ITargeted therapies are transforming brain tumor treatment by focusing on specific genetic mutations rather than broadly attacking all dividing cells. This improves precision and reduces side effects. A key example is Vorasidenib, approved for gliomas with IDH1 or IDH2 mutations, which can delay tumor progression. Researchers are also developing agents like MT-125 that disrupt cancer cell movement and increase sensitivity to radiation and chemotherapy. Gene therapies using engineered viruses aim to deliver treatment directly into tumor cells.
Immunotherapy is advancing as well. CAR T-cell therapy is being adapted for brain tumors, while oncolytic viruses like PVSRIPO selectively destroy cancer cells. Personalized cancer vaccines are also under development.
Innovative delivery methods include GammaTile, which provides localized radiation after surgery, and sonodynamic therapy, where ultrasound activates drugs to target tumor cells precisely.